Phage Biologics

Phage Biologics is a clinical-stage biotechnology company dedicated to developing advanced bacteriophage-based therapeutics to combat the global threat of antibiotic-resistant bacterial infections. The company leverages a proprietary platform to identify, select, and engineer highly specific phages that target and eliminate pathogenic bacteria while preserving the natural microbiome. Its pipeline includes programs focused on high-need areas such as chronic wound infections, respiratory infections in cystic fibrosis, and systemic multi-drug resistant conditions. By utilizing the natural precision of phages, Phage Biologics aims to provide a sustainable and effective alternative to traditional antibiotics. The company is actively advancing its lead candidates through clinical trials to demonstrate safety and efficacy in human populations.